Biomarkers in Solid Organ Transplantation

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2017 Sep 8

PMID 28880407

Citations 3

Authors

Teun van Gelder

Affiliations

Soon will be listed here.

Abstract

Recipients of solid organs such as the kidney and heart are treated with standard immunosuppressive regimens, and personalized medicine has not yet reached the clinic for this patient population. Biomarkers potentially will allow treatment regimens to be adjusted, according to the needs of the individual patient. Biomarkers may reflect the degree of immunosuppression of the immune system, or they may reflect early damage to the transplanted organ.

Citing Articles

Review: immunosuppression for the lung transplant patient.

Kotecha S, Ivulich S, Snell G J Thorac Dis. 2022; 13(11):6628-6644.

PMID: 34992841 PMC: 8662512. DOI: 10.21037/jtd-2021-11.

The Evolution of Lung Transplant Immunosuppression.

Ivulich S, Westall G, Dooley M, Snell G Drugs. 2018; 78(10):965-982.

PMID: 29915895 DOI: 10.1007/s40265-018-0930-6.

Biomarkers in solid organ transplantation.

van Gelder T Br J Clin Pharmacol. 2017; 83(12):2602-2604.

PMID: 28880407 PMC: 5698566. DOI: 10.1111/bcp.13391.

References

Jackson J, Kim E, Begley B, Cheeseman J, Harden T, Perez S . Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am J Transplant. 2011; 11(10):2228-34. PMC: 3184377. DOI: 10.1111/j.1600-6143.2011.03680.x. View

Millan O, Budde K, Sommerer C, Aliart I, Rissling O, Bardaji B . Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation. Br J Clin Pharmacol. 2017; 83(12):2636-2650. PMC: 5698579. DOI: 10.1111/bcp.13399. View

Tang J, de Winter B, Hesselink D, Sombogaard F, Wang L, van Gelder T . The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients. Br J Clin Pharmacol. 2016; 83(4):812-822. PMC: 5346874. DOI: 10.1111/bcp.13154. View

Kho M, Cransberg K, Weimar W, van Gelder T . Current immunosuppressive treatment after kidney transplantation. Expert Opin Pharmacother. 2011; 12(8):1217-31. DOI: 10.1517/14656566.2011.552428. View

Colvin M, Smith C, Tullius S, Goldstein D . Aging and the immune response to organ transplantation. J Clin Invest. 2017; 127(7):2523-2529. PMC: 5490761. DOI: 10.1172/JCI90601. View

Bloom R, Bromberg J, Poggio E, Bunnapradist S, Langone A, Sood P . Cell-Free DNA and Active Rejection in Kidney Allografts. J Am Soc Nephrol. 2017; 28(7):2221-2232. PMC: 5491290. DOI: 10.1681/ASN.2016091034. View

Brunet M, Shipkova M, van Gelder T, Wieland E, Sommerer C, Budde K . Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. Ther Drug Monit. 2016; 38 Suppl 1:S1-20. DOI: 10.1097/FTD.0000000000000287. View

Glander P, Sombogaard F, Budde K, van Gelder T, Hambach P, Liefeldt L . Improved assay for the nonradioactive determination of inosine 5'-monophosphate dehydrogenase activity in peripheral blood mononuclear cells. Ther Drug Monit. 2009; 31(3):351-9. DOI: 10.1097/FTD.0b013e31819c3f3d. View

Schaub S, Nickerson P, Rush D, Mayr M, Hess C, Golian M . Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am J Transplant. 2009; 9(6):1347-53. DOI: 10.1111/j.1600-6143.2009.02645.x. View

10.

Budde K, Sommerer C, Rissling O, Dieterlen M, Barten M . Target Enzyme Activity and Phosphorylation of Pathway Molecules As Specific Biomarkers in Transplantation. Ther Drug Monit. 2016; 38 Suppl 1:S43-9. DOI: 10.1097/FTD.0000000000000288. View

11.

Budde K, Matz M, Durr M, Glander P . Biomarkers of over-immunosuppression. Clin Pharmacol Ther. 2011; 90(2):316-22. DOI: 10.1038/clpt.2011.111. View

12.

van Gelder T . Biomarkers in solid organ transplantation. Br J Clin Pharmacol. 2017; 83(12):2602-2604. PMC: 5698566. DOI: 10.1111/bcp.13391. View